Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Acarix AB's change in receivables for the quarter that ended in Mar. 2026 was €1.07 Mil. It means Acarix AB's Accounts Receivable
declined by €1.07 Mil
from Dec. 2025 to Mar. 2026 .
Acarix AB's change in receivables for the fiscal year that ended in Dec. 2025 was €1.22 Mil. It means Acarix AB's Accounts Receivable
declined by €1.22 Mil
from Dec. 2024 to Dec. 2025 .
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Acarix AB's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 145.19.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Acarix AB's liquidation value for the
three
months ended in Mar. 2026 was €2.35 Mil.
Acarix AB (FRA:7AC) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Acarix AB's Days Sales Outstanding for the quarter that ended in Mar. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acarix AB Change In Receivables Related Terms
Acarix AB Change In Receivables Historical Data
* Premium members only.
The historical data trend for Acarix AB's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.27 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Change In Receivables of €1.27 Mil mean?
Acarix AB (FRA:7AC) has a Change In Receivables of €1.27 Mil as of Mar. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Acarix AB and its competitors.
Is Acarix AB's Change In Receivables too high?
Acarix AB's current Change In Receivables is €1.27 Mil. Overall, Acarix AB has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Acarix AB's Change In Receivables compare to ABT and SYK?
Acarix AB's Change In Receivables of €1.27 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Medical Devices & Instruments company?
A good Change In Receivables depends on the Medical Devices & Instruments industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Acarix AB and its competitors. Acarix AB's current Change In Receivables is €1.27 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acarix AB stock overvalued right now?
Acarix AB (FRA:7AC) has a current Change In Receivables of €1.27 Mil. The stock's GF Value™ is €0.01, compared to a current price of €0.02 — trading 55% above its estimated fair value. The current Change In Receivables is €1.27 Mil. Acarix AB's overall GF Score™ is 39/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Acarix AB (FRA:7AC), the current Change In Receivables is €1.27 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Acarix AB (FRA:7AC) Overvalued in 2026?
Based on GuruFocus' analysis, Acarix AB stock appears to be overvalued.
The current stock price of €0.02 is trading 55% above its estimated GF Value™ of €0.01.
Key valuation signals for FRA:7AC:
Change In Receivables: €1.27 Mil
GF Value™: €0.01 vs. price of €0.02 (55% above fair value)
No single metric tells the full story. See the FRA:7AC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acarix AB is a Swedish medical technology company that develops solutions for rapid AI-based exclusion of coronary artery disease (CAD). Its CE-marked CADScor System, which has also received DeNovo approval from the FDA, is intended for patients experiencing chest pain with suspected coronary artery disease and is designed to help reduce millions of cases of unnecessary, invasive, and costly diagnostics. Acarix recommends the CADScor System as a first-line diagnostic tool that uses sensitive acoustics and computational processing to analyze coronary blood flow to rule out coronary artery disease (CAD), with a majority certainty at the point of care. Geographically, the company generates maximum revenue from the United States, and the rest from Germany, Sweden, Iraq, and other regions.
39GF Score
Get the complete analysis for FRA:7AC
Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7AC has been successfully added to your 
